IvelinRadkov Sanofi (NASDAQ:SNY) and its partner Regeneron (NASDAQ:REGN) announced Wednesday that the EU drug regulator, the European Medicines Agency (EMA), has approved a label expansion for their asthma therapy Dupixent to include patients with the lung disorder, chronic obstructive pulmonary disease (COPD). The approval marks the first time a globalContinue Reading
Panama7/iStock Editorial via Getty Images Sanofi (NASDAQ:SNY) has sought initial bids for its $20B consumer healthcare spinoff as the French drugmaker moves forward with its divestment plans, which include a potential public listing, Bloomberg News reported Tuesday, citing people familiar with the matter. According to the people, the Paris-based pharmaContinue Reading
RomanBabakin Sanofi (NASDAQ:SNY) is up ~3% in Monday afternoon trading as it stands to benefit from positive data released earlier in the day on Alnylam Pharmaceuticals’ (ALNY) Amvuttra (vutrisiran) The data was on the drug in treating ATTR amyloidosis with cardiomyopathy. The therapoy was already approved for polyneuropathy of hereditaryContinue Reading
